Global nanotech drug delivery expected to soar to $136B by 2021; Industry, academics link on biodegradable regenerative stent;

> The global market for nanotechnology-enabled drug delivery therapeutics will grow from $2.3 billion today to $136 billion by 2021, according to a new report from market analyst firm ResearchMoz. Release

> Revenue from Becton Dickinson's ($BDX) Medical division, which sells drug delivery systems, diabetes care and disposable products, jumped 2.6% to $950 million in the fiscal first quarter that ended Dec. 31, Reuters reports. Story

> Dutch specialty pharmaceutical company OctoPlus will work with Ferring Pharmaceuticals to develop an undisclosed compound. OctoPlus is known, in part, for supplying drug delivery tech to develop controlled-release versions of both existing and new drugs. Release

> QualiMed Innovative Medizinprodukte of Hamburg, Germany, along with Yale University, University College of London and others will work on developing a functioning biodegradable regenerative stent. Release

> Kedem Pharmaceuticals will profile its sublingual (under the tongue) drug delivery technology at the World Money Show in Orlando, FL, Feb. 9-12, and present an update on X-Excite, its lead drug for erectile dysfunction. Release

> Generic drug maker Mylan ($MYL) has acquired manufacturing and marketing rights to two skin drugs from Valeant Pharmaceuticals ($VRX). One is a generic acne gel treatment; the other is a drug cream for basal cell carcinomas and actinic or solar keratosis, according to Drugstorenews.com. Story

Suggested Articles

Swiss scientists are using ultrasound to trap and deliver drugs in the brain, a non-invasive delivery method that could help target tumors, too.

Alexion's 100 mg/ml Ultomiris formulation is expected to slash infusion times by about 60% and bodes well for a planned subcutaneous version, too.

Kindeva, which produces inhalers, transdermal patches and other medical devices, is expanding operations in the St. Paul, Minnesota, area.